Press release
Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024
Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Global nonalcoholic steatohepatitis (NASH) treatment market was valued at US$ XX Mn in 2017 and expected to grow at 15.0% Compound Annual Growth Rate (CAGR) over 2018 to 2024
Market Outline: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Nonalcoholic steatohepatitis (NASH) treatment or fatty liver disease develop in the nonalcoholic humans that causes the liver damage which is diagnostically similar to alcoholic hepatitis. Nonalcoholic steatohepatitis may also causes due to glucose intolerance, dyslipidemia, and obesity. NASH is a silent disease with few or no symptoms. Currently a few drugs are available in the market for the treatment of nonalcoholic steatohepatitis treatment.
Market Dynamics: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Increase in the prevalence of metabolic disorders such as diabetes and dyslipidemia are expected to drive the NASH Treatment Market. Moreover, rise in R&D for the innovation of novel therapeutics for NASH disease, promising pipeline products, and change in lifestyle are anticipated to boost the nonalcoholic steatohepatitis treatment market over the forecast period. However, lack of efficient disease diagnosis procedures in early stage, poor understanding of disease pathophysiology, and large medical unmet need may impede the growth of nonalcoholic steatohepatitis market.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/#ulp-4H8Z4LpNMLEuOnnx
Market Scope: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Global nonalcoholic steatohepatitis (NASH) treatment market is segmented based on the product type and distribution channel
Based on the product type, the market is segmented into the following:
• Simtuzumab and Liraglutide
• GFT 505
• Vitamin E
• Obeticholic Acid (INT-747)
• Pioglitazone
• Others
Based on the distribution channel, the market is segmented into the following:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/#ulp-c654SbFYO64MsOhu
Regional Analysis: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Geographically, global nonalcoholic steatohepatitis (NASH) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America nonalcoholic steatohepatitis (NASH) treatment market growth driven by increase in the prevalence of NASH disease due to rise in obesity and metabolic disorders (according to American Liver Foundation, approximately 12% of total population has NASH and 3% has advanced liver fibrosis due to NASH) and change in lifestyle are anticipated to fuel the market. Europe nonalcoholic steatohepatitis (NASH) treatment market expected to exhibit lucrative growth due to increase in the R&D for the innovation of newer drugs, rise in prevalence of NASH due to metabolic disorders, and increase in healthcare expenditure. However, a significant growth rate observed in Asia Pacific nonalcoholic steatohepatitis (NASH) treatment market owing to entry of market players into Asia Pacific region, large patient pool, and rise in healthcare expenditure are expected to bolster the market in the region.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/#ulp-14mlyhjMGhVjZqa3
Competition Assessment: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
Some of the players in the global nonalcoholic steatohepatitis (NASH) treatment market include:
• Zydus Cadila (India)
• Genfit SA (France)
• AstraZeneca Plc (UK)
• Gilead Sciences, Inc. (U.S.)
• Conatus Pharmaceuticals, Inc. (U.S.)
• Galmed Pharmaceuticals Ltd (Israel)
• Immuron (Australia)
• Intercept Pharmaceuticals, Inc. (U.S.)
• Tobira Therapeutics, Inc. (U.S.)
• Galectin Therapeutics, Inc. (U.S)
Notable Market Developments: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
In December 2017, Galectin Therapeutics announced the Phase 2b clinical trial results of GR-MD-02 which showed significant results in NASH cirrhosis patients
In January 2018, Genfit started the clinical trials for Children with NASH disease in US with the drug elafibranor
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/nonalcoholic-steatohepatitis-nash-treatment-market/
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024 here
News-ID: 1061441 • Views: …
More Releases from Precision Business Insights
Gaming Controller Market Rising Demand for Gaming Stations and eSports
According to the Precision Business Insights (PBI), latest report the gaming controller market size was valued at USD 2,382.1 million in 2023, growing at an 8.5% CAGR from 2024 to 2030. The key drivers of the expansion of the global gaming controller include the enhanced gaming experience, technology advancements, consumer preferences and ergonomics, competitive gaming and esports, intuitiveness, and portability of the gaming controllers.
View Full Report: https://www.precisionbusinessinsights.com/market-reports/gaming-controller-market …
Next Generation Dietary Supplements Market Size, Growth Opportunities 2024-2030
According to Precision Business Insights (PBI), the latest report, the global next-generation dietary supplements market was valued at USD 10,752.3 million in 2023 and is expected to grow at a CAGR of 8.8% from 2024-2030. The primary factors that drive the market are the growing demand for rising consumer knowledge of the various health benefits of Next Generation Dietary Supplements, as well as rising disposable income levels, fuel market expansion…
Catamaran Market Increasing Popularity Of Water Sports And Fishing Activities
According to Precision Business Insights (PBI), the latest report, the catamaran market is valued at USD 1,635.7 million in 2023 and is anticipated to grow a CAGR of 4.9% over the forecast period. The primary factors that drive the market are the growing demand for Catamaran pushes the market to enhance efficiency, minimize time consumption, and reduce post-harvest operating losses. Catamaran are good solutions for reducing high labour costs since…
Refrigerated Display Cases Market Size, Share, Growth Trends and Forecast 2024-2 …
According to Precision Business Insights (PBI), latest report, the refrigerated display cases market was valued at USD 8,248.5 million in 2023 and is expected to grow at a 5.1% CAGR from 2024 to 2030. The primary drivers of the expansion of the global refrigerated display cases market include the increasing demand for frozen food and drinks among urban consumers. In addition, growing awareness about environment sustainability and energy efficiency is…
More Releases for NASH
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
